Darzalex for ITP – pro
Daratumumab, an anti-CD38 monoclonal antibody developed to target tumoral plasma cells in multiple myeloma, 4 was recently found to be effective in antibody-mediated diseases, such as autoimmune cytopenia following hematopoietic stem cell transplantation and systemic lupus. There are also studies for ITP: in majority, case reports One trial is ongoing in phase 2; no results are yet available.
Crickx E, Audia S, Robbins A, Boutboul D, Comont T, Cheminant M, Oksenhendler E, Godeau B, Michel M, Mahevas M. Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia. Haematologica. 2021 Dec 1;106(12):3198-3201. doi: 10.3324/haematol.2021.279232. PMID: 34348453; PMCID: PMC8634173.
Strüßmann T, Jung J, Heinz J, Duque Afonso J, Wäsch R, Engelhardt M, Duyster J, Finke J, Marks R. Long-term complete remission of refractory severe idiopathic immune thrombocytopenia (ITP) treated with daratumumab. Ann Hematol. 2023 Jan;102(1):245-247. doi: 10.1007/s00277-022-05035-y. Epub 2022 Nov 17. PMID: 36394581; PMCID: PMC9807464.
Ilze Vernava et al, Daratumumab as a novel treatment option in refractory ITP. Blood Cells, Molecules, and Diseases
Volume 99, March 2023, 102724
Yazan Migdady,et al, Successful treatment of thrombocytopenia with daratumumab after allogeneic transplant: a case report and literature review. Blood Adv (2020) 4 (5): 815–818.
Hanny Al-Samkari, 2025 update on clinical trials in immune thrombocytopenia. Am J Hematology Volume99, Issue11
November 2024 Pages 2178-2190